In vivo activity of Nisin A and Nisin v against Listeria monocytogenes in mice

BMC Microbiology

Volumn 13, Issue 1, 2013, Pages

  Campion, Alicia ^a   Casey, Pat G ^a,c   Field, Des ^a   Cotter, Paul D ^b,c   Hill, Colin ^a,c   Ross, R Paul ^b,c  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b TEAGASC FOOD RESEARCH CENTRE   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antimicrobial; Bacteriocin; Lantibiotic; Mutagenesis; Nisin; Peptide engineering

Indexed keywords

NISIN A; NISIN V; PHOSPHATE BUFFERED SALINE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BIOLUMINESCENCE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; IN VIVO STUDY; INFECTION CONTROL; LISTERIA MONOCYTOGENES; LISTERIOSIS; LIVER; MOUSE; NONHUMAN; SPLEEN;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; LISTERIA MONOCYTOGENES; LISTERIOSIS; MICE; MICE, INBRED BALB C; NISIN; TREATMENT OUTCOME; WHOLE BODY IMAGING;

ANIMALIA; LISTERIA MONOCYTOGENES; MURINAE; MUS; POSIBACTERIA;

EID: 84873028768     PISSN: None     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-13-23     Document Type: Article

References (46)

1. Limiting factors in the lactic fermentation. Rogers LA, Whittier EO, J Bacteriol 1928 16 211 229 16559334
2. Bacteriocins and their food applications. Chen H, Hoover DG, Comprehensive Rev Food Sci Food Safety 2003 2 82 100
3. Nisin and its uses as a food preservative. Delves-Broughton J, Food Technol 1990 44 100 117
4. Microbial solutions to microbial problems; lactococcal bacteriocins for the control of undesirable biota in food. Guinane CM, Cotter PD, Hill C, Ross RP, J Appl Microbiol 2005 98 1316 1325 10.1111/j.1365-2672.2005.02552.x 15916645
5. Maturation pathway of nisin and other lantibiotics: post-translationally modified antimicrobial peptides exported by Gram-positive bacteria. de Vos WM, Kuipers OP, van der Meer JR, Siezen RJ, Mol Microbiol 1995 17 427 437 10.1111/j.1365-2958.1995.mmi-17030427.x 8559062
6. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications. Sahl H, Jack R, Bierbaum G, Eur J Biochem 1995 230 827 853 10.1111/j.1432-1033.1995.tb20627.x 7601145
7. Lantibiotics: mode of action, biosynthesis and bioengineering. Bierbaum G, Sahl HG, Curr Pharm Biotechnol 2009 10 2 18 10.2174/138920109787048616 19149587
8. The nisin-lipid II complex reveals a pyrophosphate cage that provides a blueprint for novel antibiotics. Hsu ST, Breukink E, Tischenko E, Lutters MA, de Kruijff B, Kaptein R, Bonvin AM, van Nuland NA, Nat Struct Mol Biol 2004 11 963 967 10.1038/nsmb830 15361862
9. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG, J Biol Chem 2001 276 1772 1779 11038353
10. Lipid II-mediated pore formation by the peptide antibiotic nisin: a black lipid membrane study. Wiedemann I, Benz R, Sahl HG, J Bacteriol 2004 186 3259 3261 10.1128/JB.186.10.3259-3261.2004 15126490
11. Bacterial lantibiotics: strategies to improve therapeutic potential. Cotter PD, Hill C, Ross RP, Curr Protein Pept Sci 2005 6 61 75 10.2174/1389203053027584 15638769
12. Discovery of medically significant lantibiotics. Piper C, Cotter PD, Ross RP, Hill C, Curr Drug Discov Technol 2009 6 1 18 10.2174/157016309787581075 19275538
13. Two-peptide lantibiotics: a medical perspective. Lawton EM, Ross RP, Hill C, Cotter PD, Mini Rev Med Chem 2007 7 1236 1247 10.2174/138955707782795638 18220976
14. New antibiotic compound enters phase I clinical trial, http://www.wellcome.ac.uk/News/2011/News/WTVM053339.htm
15. Microbisporicin gene cluster reveals unusual features of lantibiotic biosynthesis in actinomycetes. Foulston LC, Bibb MJ, Proc Natl Acad Sci U S A 2010 107 13461 13466 10.1073/pnas.1008285107 20628010
16. Efficacy of the new lantibiotic NAI-107 in experimental infections induced by MDR Gram-positive pathogens. Jabes D, Brunati C, Candiani G, Riva S, Romano G, Donadio S, Antimicrob Agents Chemother 2011 55 1671 1676 10.1128/AAC.01288-10 21220527
17. Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics. Smith L, Hillman J, Curr Opin Microbiol 2008 11 401 408 10.1016/j.mib.2008.09.008 18848642
18. The lantibiotic lacticin 3147 prevents systemic spread of Staphylococcus aureus in a murine infection model. Piper C, Casey PG, Hill C, Cotter PD, Int J Microbiol 2012 2012.
19. Antibacterial efficacy of nisin against multidrug-resistant Gram-positive pathogens. Severina E, Severin A, Tomasz A, J Antimicrob Chemother 1998 41 341 347 10.1093/jac/41.3.341 9578160
20. Nisin, alone and combined with peptidoglycan-modulating antibiotics: activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Brumfitt W, Salton MR, Hamilton-Miller JM, J Antimicrob Chemother 2002 50 731 734 10.1093/jac/dkf190 12407132
21. A comparison of the activities of lacticin 3147 and nisin against drug-resistant Staphylococcus aureus and Enterococcus species. Piper C, Draper LA, Cotter PD, Ross RP, Hill C, J Antimicrob Chemother 2009 63 546 551
22. Bioengineering of a nisin A-producing Lactococcus lactis to create isogenic strains producing the natural variants nisin F, Q and Z. Piper C, Hill C, Cotter PD, Ross RP, Microb Biotechnol 2011 4 375 382 10.1111/j.1751-7915. 2010.00207.x 21375711
23. Lactation mastitistherapy with the nisin-based product MastOut: results of a 125-cow study. Coughlin R, Tikofsky L, Schulte H, Bennett G, Rejman J, Fisher D, Crabb J, Schukken Y, National Mastitis Council Annual Meeting 2004 43 296 297
24. Activity of nisin against Streptococcus pneumoniae, in vitro, and in a mouse infection model. Goldstein BP, Wei J, Greenberg K, Novick R, J Antimicrob Chemother 1998 42 277 278 10.1093/jac/42.2.277 9738856
25. The treatment of bovine streptococcal and staphylococcal mastitis with nisin. Taylor J, Hirsch AR, Mattick AT, Vet Res 1949 61 197 198
26. Efficacy of nisin in treatment of clinical mastitis in lactating dairy cows. Cao LT, Wu JQ, Xie F, Hu SH, Mo Y, J Dairy Sci 2007 90 3980 3985 10.3168/jds.2007-0153 17639009
27. Therapeutic effect of nisin Z on subclinical mastitis in lactating cows. Wu J, Hu S, Cao L, Antimicrob Agents Chemother 2007 51 3131 3135 10.1128/AAC.00629-07 17606675
28. Nisin F in the treatment of respiratory tract infections caused by Staphylococcus aureus. De Kwaadsteniet M, Doeschate KT, Dicks LM, Lett Appl Microbiol 2009 48 65 70 10.1111/j.1472-765X.2008.02488.x 19018962
29. The ability of nisin F to control Staphylococcus aureus infection in the peritoneal cavity, as studied in mice. Brand AM, De Kwaadsteniet M, Dicks LMT, Lett Appl Microbiol 2010 51 645 649 10.1111/j.1472-765X.2010.02948.x 21029139
30. Nisin F-loaded brushite bone cement prevented the growth of Staphylococcus aureus in vivo. van Staden AD, Brand AM, Dicks LMT, J Appl Microbiol 2012 112 831 840 10.1111/j.1365-2672.2012.05241.x 22268790
31. The dawning of a 'Golden era' in lantibiotic bioengineering. Field D, Hill C, Cotter PD, Ross RP, Mol Microbiol 2010 78 1077 1087 10.1111/j.1365-2958. 2010.07406.x 21091497
32. The generation of nisin variants with enhanced activity against specific Gram-positive pathogens. Field D, O'Connor PM, Cotter PD, Hill C, Ross RP, Mol Microbiol 2008 69 218 230 10.1111/j.1365-2958.2008.06279.x 18485077
33. The gene encoded antimicrobial peptides, a template for the design of novel anti-mycobacterial drugs. Carroll J, Field D, O' Connor PM, Cotter PD, Coffey A, Hill C, Ross RP, O' Mahony J, Bioengineered Bugs 2010 1 408 412 10.4161/bbug.1.6.13642 21468208
34. Studies with bioengineered nisin peptides highlight the broad-spectrum potency of nisin V. Field D, Quigley L, O'Connor PM, Rea MC, Daly K, Cotter PD, Hill C, Ross RP, Microb Biotechnol 2010 3 473 486 10.1111/j.1751-7915.2010. 00184.x 21255345
35. Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Riedel CU, Monk IR, Casey PG, Morrissey D, O'Sullivan GC, Tangney M, Hill C, Gahan CGM, Appl Environ Microbiol 2007 73 3091 3094 10.1128/AEM.02940-06 17351089
36. The bacteriocin piscicolin 126 retains antilisterial activity in vivo. Ingham A, Ford M, Moore RJ, Tizard M, J Antimicrob Chemother 2003 51 1365 1371 10.1093/jac/dkg229 12716771
37. In vivo study on the effectiveness of pediocin PA-1 and Pediococcus acidilactici UL5 at inhibiting Listeria monocytogenes. Dabour N, Zihler A, Kheadr E, Lacroix C, Fliss I, Int J Food Microbiol 2009 133 225 233 10.1016/j.ijfoodmicro.2009.05.005 19541383
38. Investigation of the cytotoxicity of eukaryotic and prokaryotic antimicrobial peptides in intestinal epithelial cells in vitro. Maher S, McClean S, Biochem Pharmacol 2006 71 1289 1298 10.1016/j.bcp.2006.01.012 16530733
39. Evaluation of developmental toxicity of microbicide nisin in rats. Gupta SM, Aranha CC, Reddy KV, Food Chem Toxicol 2008 46 598 603 10.1016/j.fct.2007. 09.006 17949878
40. Some chemical and physical properties of nisin, a small-protein antibiotic produced by Lactococcus lactis. Liu W, Hansen JN, Appl Environ Microbiol 1990 56 2551 2558 2119570
41. Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ, Appl Environ Microbiol 1995 61 2873 2878 7487019
42. Bioengineered nisin derivatives with enhanced activity in complex matrices. Rouse S, Field D, Daly KM, O'Connor PM, Cotter PD, Hill C, Ross RP, Microb Biotechnol 2012 5 501 508 10.1111/j.1751-7915.2011.00324.x 22260415
43. Site-directed mutagenesis of the hinge region of nisin Z and properties of nisin Z mutants. Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD, Appl Microbiol Biotechnol 2004 64 806 815 10.1007/s00253-004-1599-1 15048591
44. Bioengineered nisin A derivatives with enhanced activity against both Gram positive and Gram negative pathogens. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross RP, PLoS One 2012 7 46884 10.1371/journal.pone.0046884 23056510
45. A 90-day oral toxicity study of nisin A, an anti-microbial peptide derived from Lactococcus lactis subsp. lactis, in F344 rats. Hagiwara A, Imai N, Nakashima H, Toda Y, Kawabe M, Furukawa F, Delves-Broughton J, Yasuhara K, Hayashi S-M, Food Chem Toxicol 2010 48 2421 2428 10.1016/j.fct.2010.06.002 20621644
46. Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Kuipers OP, Beerthuyzen MM, Siezen RJ, De Vos WM, Eur J Biochem 1993 216 281 291 10.1111/j.1432-1033.1993.tb18143.x 7689965